Cargando…

Biochemical and pathological changes result from mutated Caveolin-3 in muscle

BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So...

Descripción completa

Detalles Bibliográficos
Autores principales: González Coraspe, José Andrés, Weis, Joachim, Anderson, Mary E., Münchberg, Ute, Lorenz, Kristina, Buchkremer, Stephan, Carr, Stephanie, Zahedi, René Peiman, Brauers, Eva, Michels, Hannah, Sunada, Yoshihide, Lochmüller, Hanns, Campbell, Kevin P., Freier, Erik, Hathazi, Denisa, Roos, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114045/
https://www.ncbi.nlm.nih.gov/pubmed/30153853
http://dx.doi.org/10.1186/s13395-018-0173-y
_version_ 1783351123287998464
author González Coraspe, José Andrés
Weis, Joachim
Anderson, Mary E.
Münchberg, Ute
Lorenz, Kristina
Buchkremer, Stephan
Carr, Stephanie
Zahedi, René Peiman
Brauers, Eva
Michels, Hannah
Sunada, Yoshihide
Lochmüller, Hanns
Campbell, Kevin P.
Freier, Erik
Hathazi, Denisa
Roos, Andreas
author_facet González Coraspe, José Andrés
Weis, Joachim
Anderson, Mary E.
Münchberg, Ute
Lorenz, Kristina
Buchkremer, Stephan
Carr, Stephanie
Zahedi, René Peiman
Brauers, Eva
Michels, Hannah
Sunada, Yoshihide
Lochmüller, Hanns
Campbell, Kevin P.
Freier, Erik
Hathazi, Denisa
Roos, Andreas
author_sort González Coraspe, José Andrés
collection PubMed
description BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So far, more than 40 dominant pathogenic mutations have been described leading to several phenotypes many of which are associated with a mis-localization of the mutant protein to the Golgi. Golgi retention and endoplasmic reticulum (ER) stress has been demonstrated for the CAV3 p.P104L mutation, but further downstream pathophysiological consequences remained elusive so far. METHODS: We utilized a transgenic (p.P104L mutant) mouse model and performed proteomic profiling along with immunoprecipitation, immunofluorescence and immunoblot examinations (including examination of α-dystroglycan glycosylation), and morphological studies (electron and coherent anti-Stokes Raman scattering (CARS) microscopy) in a systematic investigation of molecular and subcellular events in p.P104L caveolinopathy. RESULTS: Our electron and CARS microscopic as well as immunological studies revealed Golgi and ER proliferations along with a build-up of protein aggregates further characterized by immunoprecipitation and subsequent mass spectrometry. Molecular characterization these aggregates showed affection of mitochondrial and cytoskeletal proteins which accords with our ultra-structural findings. Additional global proteomic profiling revealed vulnerability of 120 proteins in diseased quadriceps muscle supporting our previous findings and providing more general insights into the underlying pathophysiology. Moreover, our data suggested that further DGC components are altered by the perturbed protein processing machinery but are not prone to form aggregates whereas other sarcolemmal proteins are ubiquitinated or bind to p62. Although the architecture of the ER and Golgi as organelles of protein glycosylation are altered, the glycosylation of α-dystroglycan presented unchanged. CONCLUSIONS: Our combined data classify the p.P104 caveolinopathy as an ER-Golgi disorder impairing proper protein processing and leading to aggregate formation pertaining proteins important for mitochondrial function, cytoskeleton, ECM remodeling and sarcolemmal integrity. Glycosylation of sarcolemmal proteins seems to be normal. The new pathophysiological insights might be of relevance for the development of therapeutic strategies for caveolinopathy patients targeting improved protein folding capacity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13395-018-0173-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6114045
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61140452018-09-04 Biochemical and pathological changes result from mutated Caveolin-3 in muscle González Coraspe, José Andrés Weis, Joachim Anderson, Mary E. Münchberg, Ute Lorenz, Kristina Buchkremer, Stephan Carr, Stephanie Zahedi, René Peiman Brauers, Eva Michels, Hannah Sunada, Yoshihide Lochmüller, Hanns Campbell, Kevin P. Freier, Erik Hathazi, Denisa Roos, Andreas Skelet Muscle Research BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So far, more than 40 dominant pathogenic mutations have been described leading to several phenotypes many of which are associated with a mis-localization of the mutant protein to the Golgi. Golgi retention and endoplasmic reticulum (ER) stress has been demonstrated for the CAV3 p.P104L mutation, but further downstream pathophysiological consequences remained elusive so far. METHODS: We utilized a transgenic (p.P104L mutant) mouse model and performed proteomic profiling along with immunoprecipitation, immunofluorescence and immunoblot examinations (including examination of α-dystroglycan glycosylation), and morphological studies (electron and coherent anti-Stokes Raman scattering (CARS) microscopy) in a systematic investigation of molecular and subcellular events in p.P104L caveolinopathy. RESULTS: Our electron and CARS microscopic as well as immunological studies revealed Golgi and ER proliferations along with a build-up of protein aggregates further characterized by immunoprecipitation and subsequent mass spectrometry. Molecular characterization these aggregates showed affection of mitochondrial and cytoskeletal proteins which accords with our ultra-structural findings. Additional global proteomic profiling revealed vulnerability of 120 proteins in diseased quadriceps muscle supporting our previous findings and providing more general insights into the underlying pathophysiology. Moreover, our data suggested that further DGC components are altered by the perturbed protein processing machinery but are not prone to form aggregates whereas other sarcolemmal proteins are ubiquitinated or bind to p62. Although the architecture of the ER and Golgi as organelles of protein glycosylation are altered, the glycosylation of α-dystroglycan presented unchanged. CONCLUSIONS: Our combined data classify the p.P104 caveolinopathy as an ER-Golgi disorder impairing proper protein processing and leading to aggregate formation pertaining proteins important for mitochondrial function, cytoskeleton, ECM remodeling and sarcolemmal integrity. Glycosylation of sarcolemmal proteins seems to be normal. The new pathophysiological insights might be of relevance for the development of therapeutic strategies for caveolinopathy patients targeting improved protein folding capacity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13395-018-0173-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-28 /pmc/articles/PMC6114045/ /pubmed/30153853 http://dx.doi.org/10.1186/s13395-018-0173-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
González Coraspe, José Andrés
Weis, Joachim
Anderson, Mary E.
Münchberg, Ute
Lorenz, Kristina
Buchkremer, Stephan
Carr, Stephanie
Zahedi, René Peiman
Brauers, Eva
Michels, Hannah
Sunada, Yoshihide
Lochmüller, Hanns
Campbell, Kevin P.
Freier, Erik
Hathazi, Denisa
Roos, Andreas
Biochemical and pathological changes result from mutated Caveolin-3 in muscle
title Biochemical and pathological changes result from mutated Caveolin-3 in muscle
title_full Biochemical and pathological changes result from mutated Caveolin-3 in muscle
title_fullStr Biochemical and pathological changes result from mutated Caveolin-3 in muscle
title_full_unstemmed Biochemical and pathological changes result from mutated Caveolin-3 in muscle
title_short Biochemical and pathological changes result from mutated Caveolin-3 in muscle
title_sort biochemical and pathological changes result from mutated caveolin-3 in muscle
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114045/
https://www.ncbi.nlm.nih.gov/pubmed/30153853
http://dx.doi.org/10.1186/s13395-018-0173-y
work_keys_str_mv AT gonzalezcoraspejoseandres biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT weisjoachim biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT andersonmarye biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT munchbergute biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT lorenzkristina biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT buchkremerstephan biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT carrstephanie biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT zahedirenepeiman biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT brauerseva biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT michelshannah biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT sunadayoshihide biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT lochmullerhanns biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT campbellkevinp biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT freiererik biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT hathazidenisa biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle
AT roosandreas biochemicalandpathologicalchangesresultfrommutatedcaveolin3inmuscle